NPPB and hydrops fetalis: However,not so promising came the recent results from double-blind, randomized LIFE trialwhich demonstrated that in comparison to valsartan, S/V was not superior inreducing NT-proBNP levels nor in improving clinical outcomes (number of daysalive, out of hospital, and free from HF events) in comorbid HFrEF patients (NYHAclass IV) [64].